ABSTRACT Introduction: Liver represents the main place of drug metabolisation. Drugs and toxic substances reach the level of liver after absorption at gastro-intestinal level. Drug hepatotoxicity represents an important chapter of iatrogenic pathology, because the hepatic lesions induced by drugs include extremely diverse clinical, biological and histological expressions that can take the aspect of any form of acute or chronic hepatobiliary disease. Hepatic lesions induced by drugs (LHIM) represent a histological and/or biochemical alteration caused and attributed to the consumption of a drug. Hepatic elastography (Fibroscan) represents a noninvasive method of quantification of hepatic fibrosis. Material and method: We carried out a retrospective study and longitudinally prospective study that included a set of patients under treatment with Methotrexate, amounting to 76, divided into 2 subsets: a subset consisting of patients with hepatitis to Methotrexate, subset 1, of 23 patients, a subset of patients under treatment with Methotrexate but with normal hepatic samples, subset b, of 53 patients. Results: We carried out fibroscan a t a ll t he patients treated with Methotrexate, obtaining a medium score of fibrosis of 6.23 for the subset a with hepatitis at Methotrexate and of 5.33 for the subset b with normal hepatic samples. We made a correlation between the cumulated dose of Methotrexate and the
Introduction
Hepatic lesions induced by drugs (LHIM) represent a histological and/or biochemical alteration caused and attributed to the consumption of a drug. Drug hepatotoxicity represents an important chapter of iatrogenic pathology, because the hepatic lesions induced by drugs include extremely diverse clinical, biological and histological expressions that can take the aspect of any form of acute or chronic hepatobiliary disease [1, 2] .
The hepatotoxic effects caused by drugs were described starting from the 19 th century -hepatic steatosis caused by phosphorus and hepatotoxicity of tannic acid.
In the last decades a 11 time increase of LHIM is reported, due to the increase of the number 1 of used drugs but also by their more frequent recognition [3] .
The high number of chronic hepatic disorders that evolve towards hepatic fibrosis requires the creation of some new tracking and stadialization The fi brosis, which leads to various morphologic, hemodynamic and functional changes at liver level, the result being the occurrence of some quantifi able changes [4, 5, 6] .
The objectives of hepatic fi brosis are: − demonstration of lesions and their quantifi cation which allows the making of some therapeutic decisions − surveillance of the evolution of fi brosis under treatment − screening for hepatopathies with fi brosing potential.
Hepatic biopsy still represents "golden standard" for the evaluation of steatosis and hepatic fi brosis but it is an invasive method, diffi cult to accept by the patients, being also accompanied by side eff ects. Thus, at world level, the largest part of the modem researches was directed towards the implementation of some alternative non-invasive diagnosis methods that provide suffi cient accuracy so as to allow both a precise diagnosis as well as to provide the possibility of monitoring the evolution of hepatopathy by rehabilitation and reproductivity [7, 8] . The most frequent adverse eff ects of small doses of Methotrexate administered for a long time for immunosuppressive purposes as it happens in rheumatoid arthritis, psoriasis, psoriatic arthropathy, some forms of ankylosing spondylitis, can cause hepatic fi brosis with relatively increased incidence.
Material and method
We carried out a retrospective study and longitudinally prospective study that included a set of patients under treatment with Methotrexate, amounting to 76, divided into 2 subsets: a subset consisting of patients with hepatitis to Methotrexate, subset 1, of 23 patients, a subset of patients under treatment with Methotrexate but with normal hepatic samples, subset b, of 53 patients.
Inclusion criteria: 
Results

1) Distribution of the patients according to the disorder for which they have received MTX
Figure 1 Distribution of the patients according to the disorder for which they have received MTX
Most of the patients included in the study were with rheumatoid arthritis 53.94% and with Crohn disease 1,31%.
2) Structure of the 2 subsets:
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No post MTX hepatitis Post MTX hepatitis 3) Distribution of the patients of the two sets according to the medium fibrosis score (fibroscan): In our study we performed fibroscan at all the patients treated with Methotrexate, achieving a medium fi brosis score of 6.23 for the subset a with hepatitis at Methotrexate and of 5.33 for the subset b with normal hepatic samples. 
Conclusions
1.
The most frequent adverse eff ects of small doses of Methotrexate administered for a long time for immunosuppressive purposes as it happens in rheumatoid arthritis, psoriasis, psoriatic arthropathy, some forms of ankylosing spondylitis, can cause hepatic fi brosis with relatively increased incidence.
2.
Hepatic toxicity occurs after a long utilization of the treatment with Methotrexate.
3.
Alcohol consumption, antecedents of infection with B or C hepatitis virus, obesity, sugar diabetes represent risk factors for hepatic fi brosis.
4.
There is a signifi cant correlation between hepatic fi brosis induced by Methotrexate and the cumulated dose of Methotrexate. The utilization of fi broscan in monitoring treatment with Methotrexate should become a routine at all the patients for avoiding hepatic complications respectively hepatitis or hepatic cirrhosis , the method being completely painless, reproducible, with a possibility of being performed both at patients with changed values of the hepatic tests as well as those with normal values.
